top of page

Search Results

Results found for "Karuna Therapeutics"

Posts (305)

  • Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...

    August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE)--Aug. 8, 2022-- Karuna Therapeutics, Inc.

  • Why Intracellular Drugs May Hold the Key to GPCR Therapeutics

    diffusion, offset kinetics, and rebinding ✅ Real-world examples of how residence time—not potency—predicts therapeutic The slow-offset compound stays on target longer, maintains therapeutic effect as concentrations drop, DrugResidenceTime #AllostericModulation #CytosolicKinetics #PK #PD #CellPermeabilityAssays #PAMPA #Caco2 #TherapeuticKinetics

  • 📰 GPCR Weekly News, March 11 to 17, 2024

    Insights into GPCR Function Time-resolved cryo-EM of G-protein activation by a GPCR Industry News Domain Therapeutics Complex Protein Structures Newly discovered adhesion GPCR mayo controls midgut development in Drosophila Karuna Therapeutics announces that is now part of Bristol Myers Squibb GPCR Events, Meetings, and Webinars

View All

Other Pages (82)

  • Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer

    Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

  • Dr. Nicolas Gilles | Dr. GPCR Ecosystem

    He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

  • Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem

    Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

View All

Events (2)

View All
bottom of page